Travere Therapeutics (TVTX) Competitors $15.85 -0.10 (-0.62%) As of 11:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVTX vs. LNTH, RYTM, AXSM, TLX, CRSP, PCVX, CYTK, MTSR, ADMA, and KRYSShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Lantheus (LNTH), Rhythm Pharmaceuticals (RYTM), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), CRISPR Therapeutics (CRSP), Vaxcyte (PCVX), Cytokinetics (CYTK), Metsera (MTSR), ADMA Biologics (ADMA), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Travere Therapeutics vs. Its Competitors Lantheus Rhythm Pharmaceuticals Axsome Therapeutics Telix Pharmaceuticals CRISPR Therapeutics Vaxcyte Cytokinetics Metsera ADMA Biologics Krystal Biotech Lantheus (NASDAQ:LNTH) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership. Do institutionals and insiders hold more shares of LNTH or TVTX? 99.1% of Lantheus shares are owned by institutional investors. 1.5% of Lantheus shares are owned by company insiders. Comparatively, 4.2% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, LNTH or TVTX? Lantheus has a beta of 0.12, meaning that its stock price is 88% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Does the media favor LNTH or TVTX? In the previous week, Lantheus had 12 more articles in the media than Travere Therapeutics. MarketBeat recorded 16 mentions for Lantheus and 4 mentions for Travere Therapeutics. Lantheus' average media sentiment score of 1.22 beat Travere Therapeutics' score of 0.16 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 9 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend LNTH or TVTX? Lantheus presently has a consensus target price of $131.20, suggesting a potential upside of 84.51%. Travere Therapeutics has a consensus target price of $32.14, suggesting a potential upside of 102.78%. Given Travere Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Travere Therapeutics is more favorable than Lantheus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantheus 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Travere Therapeutics 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.87 Is LNTH or TVTX more profitable? Lantheus has a net margin of 16.55% compared to Travere Therapeutics' net margin of -82.88%. Lantheus' return on equity of 36.99% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lantheus16.55% 36.99% 20.55% Travere Therapeutics -82.88%-1,179.73%-41.10% Which has higher earnings and valuation, LNTH or TVTX? Lantheus has higher revenue and earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantheus$1.54B3.20$312.44M$3.5220.20Travere Therapeutics$233.18M6.04-$321.55M-$2.81-5.64 SummaryLantheus beats Travere Therapeutics on 10 of the 16 factors compared between the two stocks. Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVTX vs. The Competition Export to ExcelMetricTravere TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.41B$3.03B$5.71B$9.50BDividend YieldN/A2.40%4.60%3.99%P/E Ratio-5.6420.9227.8919.98Price / Sales6.04322.44450.69101.04Price / CashN/A43.2336.5558.97Price / Book20.868.268.615.87Net Income-$321.55M-$55.19M$3.24B$258.50M7 Day Performance-1.61%5.34%3.72%1.93%1 Month Performance6.10%17.10%10.29%12.29%1 Year Performance62.24%4.51%34.38%19.06% Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVTXTravere Therapeutics2.9965 of 5 stars$15.85-0.6%$32.14+102.8%+65.1%$1.41B$233.18M-5.64460Positive NewsUpcoming EarningsLNTHLantheus4.6972 of 5 stars$83.06+2.2%$131.20+58.0%-37.6%$5.75B$1.53B23.60700Positive NewsRYTMRhythm Pharmaceuticals3.1464 of 5 stars$89.15+2.8%$91.00+2.1%+76.9%$5.67B$130.13M-31.73140AXSMAxsome Therapeutics4.7378 of 5 stars$112.33+3.1%$172.33+53.4%+23.2%$5.53B$385.69M-19.47380Analyst RevisionTLXTelix PharmaceuticalsN/A$15.57-2.5%$22.33+43.4%N/A$5.27B$783.21M0.00N/ANews CoverageAnalyst RevisionCRSPCRISPR Therapeutics1.7287 of 5 stars$56.42-0.7%$71.75+27.2%+19.3%$4.87B$37.31M-12.48460Analyst ForecastPCVXVaxcyte1.8635 of 5 stars$36.38+1.3%$136.50+275.2%-57.4%$4.69BN/A-9.12160News CoveragePositive NewsCYTKCytokinetics4.2195 of 5 stars$38.58+4.2%$70.92+83.8%-34.3%$4.61B$18.47M-7.29250News CoveragePositive NewsMTSRMetseraN/A$42.47+8.1%$55.00+29.5%N/A$4.46BN/A0.0081Lockup ExpirationGap DownADMAADMA Biologics3.6209 of 5 stars$18.68+0.9%$27.67+48.1%+27.5%$4.46B$426.45M21.98530News CoveragePositive NewsKRYSKrystal Biotech4.8892 of 5 stars$150.41+1.5%$213.75+42.1%-27.4%$4.35B$290.52M36.16210News CoverageAnalyst Forecast Related Companies and Tools Related Companies Lantheus Competitors Rhythm Pharmaceuticals Competitors Axsome Therapeutics Competitors Telix Pharmaceuticals Competitors CRISPR Therapeutics Competitors Vaxcyte Competitors Cytokinetics Competitors Metsera Competitors ADMA Biologics Competitors Krystal Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVTX) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TVTX Stock Alerts